Kinase inhibitors and methods of use thereof

US12419885B2 · kind B2 · utility

Assignees

• The Broad Institute, Inc. · US
• DANA-FARBER CANCER INSTITUTE, INC. · US
• The General Hospital Corporation · US

Inventors

• Florence Fevrier Wagner · Ashland, US
• Jennifer Q. Pan · Acton, US
• Sivaraman Dandapani · Malden, US
• Andrew Germain · Somerville, US
• Edward Holson · Newton, US
• Benito Munoz · San Diego, US
• Partha P. Nag · Somerville, US
• Michael C. Lewis · Dedham, US
• Stephen J. Haggarty · Somerville, US
• Joshua A. Bishop · Belmont, US
• Kimberly Stegmaier · Brookline, US
• Michel Weiwer · Cambridge, US
• Versha Banerji · Winnipeg, CA

Key dates

• Filing date: Jun 10, 2021
• Grant date: Sep 23, 2025
• Expiry date: Aug 21, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3α or GSK3β) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.